Reata Pharmaceuticals Partners Again with Abbott for US$400 M Upfront
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 1 (Table of Contents)
Published: 6 Jan-2012
DOI: 10.3833/pdr.v2012.i1.1647 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Abbott has agreed to pay Reata Pharmaceuticals US$400 M upfront in order to gain a global licence to co-develop and co-commercialise the biotech’s preclinical, second-generation antioxidant inflammation modulators (AIM)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS